3B Blackbio DX Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 1 Jun 2026 | Healthcare Services | Market Cap: ₹1.0K Cr
Domestic business growth expected at 15% to 20% CAGR for the next 1-2 years (Page 20). Domestic business growth expected at 15% to 20% CAGR for the next 1-2 years; export growth targeted at 20% to 25% CAGR.
From 3B Blackbio DX Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,202
Market Cap
₹1.0K Cr
P/E Ratio
17.7
How does 3B Blackbio DX Ltd rank in Healthcare Services?
Compare 3B Blackbio DX Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
3B Blackbio DX Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹50 Cr, net profit ₹22 Cr.
Full financials →📊 Revenue & Sales Performance
- →Domestic business growth expected at 15% to 20% CAGR for the next 1-2 years (Page 20).
- →Export business projected to grow at 20% to 25% CAGR, with potential for higher growth due to tender orders (Page 19-20).
- →TRUPCR UK export revenue expected to grow by at least 30% this year, reaching INR 17-18 crores (Page 12).
- →Coris acquisition sales to grow from €5.2 million, driven by AMR products and R&D pipeline, with a conservative PCR sales estimate of €0.7-1 million over 2-3 years (Page 11-15).
- →Overall molecular diagnostics segment targeting combined growth of 15% to 20% (Page 9, 20).
- →Capacity utilization currently at 65%; expects to accommodate up to 50% growth without significant capital expenditure (Page 16-17).
- →EBITDA margins expected to stabilize around 55% due to competitive and inflationary pressures despite revenue growth (Page 16).
📈 Profitability & Margins
- →Domestic business growth expected at 15% to 20% CAGR for the next 1-2 years; export growth targeted at 20% to 25% CAGR.
- →Coris acquisition expected to contribute EUR7-8 million revenue within 2-3 years, with EBITDA margins improving to 10-15% post 2-3 years as manpower costs reduce.
- →Molecular diagnostics business projected to grow 50% from current levels without significant incremental capital investment; EBITDA margins expected to stabilize around 55% (slightly down from ~60%) due to competitive and inflationary pressures.
- →Pipeline R&D and expanding product portfolio (including AMR and PCR products) anticipated to add to top-line growth and profitability in medium term.
- →Conservative guidance given to ensure delivering above expectations; potential for big tender orders or acquisitions could spur upside beyond current projections.
- →EPS expected to improve with business scale, margin stabilization, and consolidation of Coris from H2 FY26 onwards.
🏗️ Capital Expenditure Plans
- →Molecular diagnostics business is not capital intensive; clean rooms and equipment needed are currently utilized at about 65% capacity.
- →For next 2 years, only minor capital investment expected, around INR 1 to 2 crores, mainly for facility upgrades or specific equipment for R&D.
- →No plans to buy very expensive equipment like MGS technology requiring INR 7 crores investment; alternate approaches are being used.
- →Coris acquisition is already integrated financially, with no major additional cash infusion needed for next 1-2 years due to adequate cash position.
- →The company is open to strategic acquisitions globally but currently focusing on synergies with Coris; M&A pipeline remains active.
- →Agro-chem business is static, gradual reduction in sales focus, no major capex planned there.
💰 Fundraising & Capital Structure
📋 Order Book & Pipeline
- →There is no explicit mention of a current or expected order book or specific pending orders in the provided transcript.
- →However, it is mentioned that sometimes big tender orders come unexpectedly, which cannot be projected immediately.
- →The company maintains a conservative growth estimate (e.g., 20%-25% growth in exports) partly to manage the uncertainty of large orders.
- →The management expresses optimism about growth driven by new product sales and expansion, implying a strong pipeline but no specific order backlog figures.
- →For the Coris acquisition, no immediate cash infusion for working capital or capacity is expected as they have sufficient cash and low debt.
- →The company actively pursues new acquisitions globally to synergize and grow, indicating potential future orders linked to these efforts.
Key Metrics
Frequently Asked Questions
What were 3B Blackbio DX Ltd Q1 FY26 results?
Domestic business growth expected at 15% to 20% CAGR for the next 1-2 years (Page 20). Domestic business growth expected at 15% to 20% CAGR for the next 1-2 years; export growth targeted at 20% to 25% CAGR.
What is 3B Blackbio DX Ltd share price analysis?
3B Blackbio DX Ltd currently shows a neutral. The stock trades at a P/E of 17.7 with a market cap of ₹1,036 Cr. Investors should review the full earnings analysis for detailed insights.
Is 3B Blackbio DX Ltd planning capital expenditure?
Molecular diagnostics business is not capital intensive; clean rooms and equipment needed are currently utilized at about 65% capacity.
Keep 3B Blackbio DX Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.